As the scope of pharmacy practice is expanding, a growing number of pharmacists perform physical examination (PE) to gather additional information to monitor the effectiveness and safety of their patients’ therapy. This professional activity calls for the development of comprehensive and valuable PE training. We sought to determine by consensus which PE tests should be given teaching priority in pharmacy education. Using existing PE literature in pharmacy, we conducted an online Delphi survey from December 2021 to April 2022 with 16 pharmacists who practise in a variety of settings and/or who are considered experts in PE. After 2 Delphi rounds, consensus was reached to either include or exclude 27 PE tests in entry-to-practice programs. One last round allowed prioritizing the agreed-upon PE tests in terms of educational needs. Clinicians agreed that measuring blood pressure is indispensable and should be given teaching priority, followed by pulse rate, weight and blood glucose measurements. Endocrine system and head and neck examinations should be included in pharmacy programs, but their clinical usefulness was considered less important. We compared our results with PE literature in other health care disciplines. We found that only a few PE tests truly influence drug therapy management, that some examinations can be quite difficult to perform accurately and that without proper training and opportunities to retrain, skill decay can lead to dangerous misinterpretations. Pharmacy programs should consider focusing on teaching PE tests supported by evidence as having an impact on drug therapy management. Can Pharm J (Ott) 2024;157:xx-xx.
随着药学实践范围的不断扩大，越来越多的药剂师通过进行体格检查（PE）来收集更多信息，以监测患者治疗的有效性和安全性。这项专业活动要求开展全面而有价值的 PE 培训。我们试图通过共识来确定哪些 PE 检查应在药学教育中列为教学重点。利用现有的药学 PE 文献，我们在 2021 年 12 月至 2022 年 4 月期间进行了一次在线德尔菲调查，调查对象是 16 位在不同环境中执业的药剂师和/或被认为是 PE 专家的药剂师。经过两轮德尔菲调查后，我们就 27 项 PE 测试是否纳入执业准入计划达成了共识。在最后一轮讨论中，根据教育需求对商定的 PE 检查项目进行了优先排序。临床医生一致认为，测量血压是不可或缺的，应在教学中优先考虑，其次是脉搏、体重和血糖测量。内分泌系统和头颈部检查应纳入药学课程，但其临床实用性被认为不太重要。我们将研究结果与其他医疗学科的 PE 文献进行了比较。我们发现，只有少数 PE 检查能真正影响药物治疗管理，有些检查很难准确进行，而且如果没有适当的培训和再培训机会，技能衰退会导致危险的误判。药剂学课程应考虑重点教授有证据支持的、对药物治疗管理有影响的 PE 检查。Can Pharm J (Ott) 2024;157:xx-xx.
{"title":"Setting priorities for physical examination in pharmacy education: A Delphi study","authors":"Marie-Laurence Tremblay, Marc-Antoine Guay, Alexandre Lafleur","doi":"10.1177/17151635241228259","DOIUrl":"https://doi.org/10.1177/17151635241228259","url":null,"abstract":"As the scope of pharmacy practice is expanding, a growing number of pharmacists perform physical examination (PE) to gather additional information to monitor the effectiveness and safety of their patients’ therapy. This professional activity calls for the development of comprehensive and valuable PE training. We sought to determine by consensus which PE tests should be given teaching priority in pharmacy education. Using existing PE literature in pharmacy, we conducted an online Delphi survey from December 2021 to April 2022 with 16 pharmacists who practise in a variety of settings and/or who are considered experts in PE. After 2 Delphi rounds, consensus was reached to either include or exclude 27 PE tests in entry-to-practice programs. One last round allowed prioritizing the agreed-upon PE tests in terms of educational needs. Clinicians agreed that measuring blood pressure is indispensable and should be given teaching priority, followed by pulse rate, weight and blood glucose measurements. Endocrine system and head and neck examinations should be included in pharmacy programs, but their clinical usefulness was considered less important. We compared our results with PE literature in other health care disciplines. We found that only a few PE tests truly influence drug therapy management, that some examinations can be quite difficult to perform accurately and that without proper training and opportunities to retrain, skill decay can lead to dangerous misinterpretations. Pharmacy programs should consider focusing on teaching PE tests supported by evidence as having an impact on drug therapy management. Can Pharm J (Ott) 2024;157:xx-xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"20 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139805294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
As the scope of pharmacy practice is expanding, a growing number of pharmacists perform physical examination (PE) to gather additional information to monitor the effectiveness and safety of their patients’ therapy. This professional activity calls for the development of comprehensive and valuable PE training. We sought to determine by consensus which PE tests should be given teaching priority in pharmacy education. Using existing PE literature in pharmacy, we conducted an online Delphi survey from December 2021 to April 2022 with 16 pharmacists who practise in a variety of settings and/or who are considered experts in PE. After 2 Delphi rounds, consensus was reached to either include or exclude 27 PE tests in entry-to-practice programs. One last round allowed prioritizing the agreed-upon PE tests in terms of educational needs. Clinicians agreed that measuring blood pressure is indispensable and should be given teaching priority, followed by pulse rate, weight and blood glucose measurements. Endocrine system and head and neck examinations should be included in pharmacy programs, but their clinical usefulness was considered less important. We compared our results with PE literature in other health care disciplines. We found that only a few PE tests truly influence drug therapy management, that some examinations can be quite difficult to perform accurately and that without proper training and opportunities to retrain, skill decay can lead to dangerous misinterpretations. Pharmacy programs should consider focusing on teaching PE tests supported by evidence as having an impact on drug therapy management. Can Pharm J (Ott) 2024;157:xx-xx.
随着药学实践范围的不断扩大，越来越多的药剂师通过进行体格检查（PE）来收集更多信息，以监测患者治疗的有效性和安全性。这项专业活动要求开展全面而有价值的 PE 培训。我们试图通过共识来确定哪些 PE 检查应在药学教育中列为教学重点。利用现有的药学 PE 文献，我们在 2021 年 12 月至 2022 年 4 月期间进行了一次在线德尔菲调查，调查对象是 16 位在各种环境中执业的药剂师和/或被认为是 PE 专家的药剂师。经过两轮德尔菲调查后，我们就 27 项 PE 测试是否纳入执业准入计划达成了共识。在最后一轮讨论中，根据教育需求对商定的 PE 检查项目进行了优先排序。临床医生一致认为，测量血压是不可或缺的，应在教学中优先考虑，其次是脉搏、体重和血糖测量。内分泌系统和头颈部检查应纳入药学课程，但其临床实用性被认为不太重要。我们将研究结果与其他医疗学科的 PE 文献进行了比较。我们发现，只有少数 PE 检查能真正影响药物治疗管理，有些检查很难准确进行，如果没有适当的培训和再培训机会，技能衰退会导致危险的误判。药剂学课程应考虑重点教授有证据支持的、对药物治疗管理有影响的 PE 检查。Can Pharm J (Ott) 2024;157:xx-xx.
{"title":"Setting priorities for physical examination in pharmacy education: A Delphi study","authors":"Marie-Laurence Tremblay, Marc-Antoine Guay, Alexandre Lafleur","doi":"10.1177/17151635241228259","DOIUrl":"https://doi.org/10.1177/17151635241228259","url":null,"abstract":"As the scope of pharmacy practice is expanding, a growing number of pharmacists perform physical examination (PE) to gather additional information to monitor the effectiveness and safety of their patients’ therapy. This professional activity calls for the development of comprehensive and valuable PE training. We sought to determine by consensus which PE tests should be given teaching priority in pharmacy education. Using existing PE literature in pharmacy, we conducted an online Delphi survey from December 2021 to April 2022 with 16 pharmacists who practise in a variety of settings and/or who are considered experts in PE. After 2 Delphi rounds, consensus was reached to either include or exclude 27 PE tests in entry-to-practice programs. One last round allowed prioritizing the agreed-upon PE tests in terms of educational needs. Clinicians agreed that measuring blood pressure is indispensable and should be given teaching priority, followed by pulse rate, weight and blood glucose measurements. Endocrine system and head and neck examinations should be included in pharmacy programs, but their clinical usefulness was considered less important. We compared our results with PE literature in other health care disciplines. We found that only a few PE tests truly influence drug therapy management, that some examinations can be quite difficult to perform accurately and that without proper training and opportunities to retrain, skill decay can lead to dangerous misinterpretations. Pharmacy programs should consider focusing on teaching PE tests supported by evidence as having an impact on drug therapy management. Can Pharm J (Ott) 2024;157:xx-xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139865129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.1177/17151635241228228
Laura Morrison, Jeff Nagge
Guidelines for anticoagulation management services recommend personnel be specially trained in warfarin management and suggest using tools such as decision-support software. To date, there have been no Canadian studies documenting the quality of warfarin management using a similar guideline recommended approach. A cross-sectional, retrospective observational study was conducted to measure the quality of pharmacist-led warfarin management using point-of-care international normalized ratio (INR) testing and decision-support software in various ambulatory settings in Canada. Settings included 4 family health teams in Ontario and 40 community pharmacies across Nova Scotia. Quality was measured using time in therapeutic range (TTR) and was reported in 3 manners: mean TTR, median TTR and time-weighted mean TTR. The primary outcome included 963 patients. The combined mean and median TTR for the 2019 Ontario family health teams and Nova Scotia pharmacies was 74.2% and 77.3% (interquartile range 64%-87.9%), respectively. The time-weighted mean TTR was 76.3%. To the best of our knowledge, the TTR achieved by this model of care is the highest reported in Canadian general practice. Since Thrombosis Canada defines good-quality warfarin management as a TTR of 60% or greater, and many studies have reported an association between higher TTR values and lower rates of thrombosis and hemorrhage, this model of care may have significant benefits for patients. This study demonstrates the high quality of anticoagulation management provided by specially trained pharmacists using point-of-care INR testing and decision-support software. These results support expanded access to this service for all Canadians. Can Pharm J (Ott) 2024;157:xx–xx.
{"title":"The quality of pharmacist-led community warfarin management across 2 provinces in Canada: A cross-sectional observational study","authors":"Laura Morrison, Jeff Nagge","doi":"10.1177/17151635241228228","DOIUrl":"https://doi.org/10.1177/17151635241228228","url":null,"abstract":"Guidelines for anticoagulation management services recommend personnel be specially trained in warfarin management and suggest using tools such as decision-support software. To date, there have been no Canadian studies documenting the quality of warfarin management using a similar guideline recommended approach. A cross-sectional, retrospective observational study was conducted to measure the quality of pharmacist-led warfarin management using point-of-care international normalized ratio (INR) testing and decision-support software in various ambulatory settings in Canada. Settings included 4 family health teams in Ontario and 40 community pharmacies across Nova Scotia. Quality was measured using time in therapeutic range (TTR) and was reported in 3 manners: mean TTR, median TTR and time-weighted mean TTR. The primary outcome included 963 patients. The combined mean and median TTR for the 2019 Ontario family health teams and Nova Scotia pharmacies was 74.2% and 77.3% (interquartile range 64%-87.9%), respectively. The time-weighted mean TTR was 76.3%. To the best of our knowledge, the TTR achieved by this model of care is the highest reported in Canadian general practice. Since Thrombosis Canada defines good-quality warfarin management as a TTR of 60% or greater, and many studies have reported an association between higher TTR values and lower rates of thrombosis and hemorrhage, this model of care may have significant benefits for patients. This study demonstrates the high quality of anticoagulation management provided by specially trained pharmacists using point-of-care INR testing and decision-support software. These results support expanded access to this service for all Canadians. Can Pharm J (Ott) 2024;157:xx–xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139863281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.1177/17151635241228228
Laura Morrison, Jeff Nagge
Guidelines for anticoagulation management services recommend personnel be specially trained in warfarin management and suggest using tools such as decision-support software. To date, there have been no Canadian studies documenting the quality of warfarin management using a similar guideline recommended approach. A cross-sectional, retrospective observational study was conducted to measure the quality of pharmacist-led warfarin management using point-of-care international normalized ratio (INR) testing and decision-support software in various ambulatory settings in Canada. Settings included 4 family health teams in Ontario and 40 community pharmacies across Nova Scotia. Quality was measured using time in therapeutic range (TTR) and was reported in 3 manners: mean TTR, median TTR and time-weighted mean TTR. The primary outcome included 963 patients. The combined mean and median TTR for the 2019 Ontario family health teams and Nova Scotia pharmacies was 74.2% and 77.3% (interquartile range 64%-87.9%), respectively. The time-weighted mean TTR was 76.3%. To the best of our knowledge, the TTR achieved by this model of care is the highest reported in Canadian general practice. Since Thrombosis Canada defines good-quality warfarin management as a TTR of 60% or greater, and many studies have reported an association between higher TTR values and lower rates of thrombosis and hemorrhage, this model of care may have significant benefits for patients. This study demonstrates the high quality of anticoagulation management provided by specially trained pharmacists using point-of-care INR testing and decision-support software. These results support expanded access to this service for all Canadians. Can Pharm J (Ott) 2024;157:xx–xx.
{"title":"The quality of pharmacist-led community warfarin management across 2 provinces in Canada: A cross-sectional observational study","authors":"Laura Morrison, Jeff Nagge","doi":"10.1177/17151635241228228","DOIUrl":"https://doi.org/10.1177/17151635241228228","url":null,"abstract":"Guidelines for anticoagulation management services recommend personnel be specially trained in warfarin management and suggest using tools such as decision-support software. To date, there have been no Canadian studies documenting the quality of warfarin management using a similar guideline recommended approach. A cross-sectional, retrospective observational study was conducted to measure the quality of pharmacist-led warfarin management using point-of-care international normalized ratio (INR) testing and decision-support software in various ambulatory settings in Canada. Settings included 4 family health teams in Ontario and 40 community pharmacies across Nova Scotia. Quality was measured using time in therapeutic range (TTR) and was reported in 3 manners: mean TTR, median TTR and time-weighted mean TTR. The primary outcome included 963 patients. The combined mean and median TTR for the 2019 Ontario family health teams and Nova Scotia pharmacies was 74.2% and 77.3% (interquartile range 64%-87.9%), respectively. The time-weighted mean TTR was 76.3%. To the best of our knowledge, the TTR achieved by this model of care is the highest reported in Canadian general practice. Since Thrombosis Canada defines good-quality warfarin management as a TTR of 60% or greater, and many studies have reported an association between higher TTR values and lower rates of thrombosis and hemorrhage, this model of care may have significant benefits for patients. This study demonstrates the high quality of anticoagulation management provided by specially trained pharmacists using point-of-care INR testing and decision-support software. These results support expanded access to this service for all Canadians. Can Pharm J (Ott) 2024;157:xx–xx.","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"49 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139803122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-01DOI: 10.1177/17151635241229059
Stephanie C. Gysel, Ross T. Tsuyuki
{"title":"The pharmacist primary care clinic: The evolution of pharmacy practice?","authors":"Stephanie C. Gysel, Ross T. Tsuyuki","doi":"10.1177/17151635241229059","DOIUrl":"https://doi.org/10.1177/17151635241229059","url":null,"abstract":"","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"28 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139814429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-01DOI: 10.1177/17151635241229059
Stephanie C. Gysel, Ross T. Tsuyuki
{"title":"The pharmacist primary care clinic: The evolution of pharmacy practice?","authors":"Stephanie C. Gysel, Ross T. Tsuyuki","doi":"10.1177/17151635241229059","DOIUrl":"https://doi.org/10.1177/17151635241229059","url":null,"abstract":"","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"31 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139874037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-18DOI: 10.1177/17151635231219546
Yasmin Abdul Aziz, Vivian Ng, Diya Srinivasan, Julie Vo, Laura Desveaux, Kevin Schwartz, Z. Rosenberg-Yunger, Erin Berenbaum, Lindsay Friedman, Bradley Langford, Valerie Leung, Emily Angl, Nardine Nakhla, Mina Tadrous, Barbara Farrell, Mathew DeMarco, Nancy Waite, Lisa Dolovich, Mansur Mehdi, Jon Jones, Humayra Tasnim, Mhd Wasem, E. Alsabbagh, Kelly Neiterman, Grindrod, Kristy Scarfone, Shaleesa Ledlie, D. Shearer, Tara Gomes
BACKGROUND: Expanding pharmacists' scope of practice to include prescribing for thirteen minor ailments, including infectious diseases, in the community pharmacy setting began January 2023. This expansion presents opportunities to improve patients’ access to timely care and harness pharmacists’ expertise to increase appropriate prescribing. Identifying key facilitators and barriers for the effective implementation of pharmacist prescribing is crucial to proactively support this evolution. OBJECTIVE : To identify facilitators and barriers for the effective implementation of pharmacists prescribing medications for selected minor ailments and infectious diseases METHODS : Virtual interviews and online surveys were utilized to gather pharmacists’ perspectives on service provision across Ontario prior to the launch. Virtual focus group discussions were conducted with primary care physicians and patients separately. Focus groups and interviews were audio recorded, transcribed verbatim and thematically analyzed. Data analysis was guided by the Consolidated Framework for Implementation Research (CFIR) and the Theoretical Domains Framework
{"title":"OPEN Summit 2023 Abstracts–Poster and Oral Presentations","authors":"Yasmin Abdul Aziz, Vivian Ng, Diya Srinivasan, Julie Vo, Laura Desveaux, Kevin Schwartz, Z. Rosenberg-Yunger, Erin Berenbaum, Lindsay Friedman, Bradley Langford, Valerie Leung, Emily Angl, Nardine Nakhla, Mina Tadrous, Barbara Farrell, Mathew DeMarco, Nancy Waite, Lisa Dolovich, Mansur Mehdi, Jon Jones, Humayra Tasnim, Mhd Wasem, E. Alsabbagh, Kelly Neiterman, Grindrod, Kristy Scarfone, Shaleesa Ledlie, D. Shearer, Tara Gomes","doi":"10.1177/17151635231219546","DOIUrl":"https://doi.org/10.1177/17151635231219546","url":null,"abstract":"BACKGROUND: Expanding pharmacists' scope of practice to include prescribing for thirteen minor ailments, including infectious diseases, in the community pharmacy setting began January 2023. This expansion presents opportunities to improve patients’ access to timely care and harness pharmacists’ expertise to increase appropriate prescribing. Identifying key facilitators and barriers for the effective implementation of pharmacist prescribing is crucial to proactively support this evolution. OBJECTIVE : To identify facilitators and barriers for the effective implementation of pharmacists prescribing medications for selected minor ailments and infectious diseases METHODS : Virtual interviews and online surveys were utilized to gather pharmacists’ perspectives on service provision across Ontario prior to the launch. Virtual focus group discussions were conducted with primary care physicians and patients separately. Focus groups and interviews were audio recorded, transcribed verbatim and thematically analyzed. Data analysis was guided by the Consolidated Framework for Implementation Research (CFIR) and the Theoretical Domains Framework","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"50 ","pages":"S1 - S45"},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.1177/17151635231217196
Daniel Burton, Stephanie Gysel, Ross T. Tsuyuki
{"title":"Why we need to incorporate obesity medicine into community pharmacies","authors":"Daniel Burton, Stephanie Gysel, Ross T. Tsuyuki","doi":"10.1177/17151635231217196","DOIUrl":"https://doi.org/10.1177/17151635231217196","url":null,"abstract":"","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"8 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138586286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.1177/17151635231216119
Tarek Hussein, Nia Cartright, Jenny Kirschner, Arun Nadarasa, A. Rathbone, Laura Lindsey
{"title":"Social prescribing in pharmacies: What is it, does it work and what does it mean for Canadian pharmacies?","authors":"Tarek Hussein, Nia Cartright, Jenny Kirschner, Arun Nadarasa, A. Rathbone, Laura Lindsey","doi":"10.1177/17151635231216119","DOIUrl":"https://doi.org/10.1177/17151635231216119","url":null,"abstract":"","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"43 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138587484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.1177/17151635231215061
N. Yuksel, Anne Marie Whelan
{"title":"A practice tool for initiating and managing combined hormonal contraceptives for contraception: Assessment, decision-making and monitoring","authors":"N. Yuksel, Anne Marie Whelan","doi":"10.1177/17151635231215061","DOIUrl":"https://doi.org/10.1177/17151635231215061","url":null,"abstract":"","PeriodicalId":9476,"journal":{"name":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","volume":"47 22","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138588666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：